Evidence-Based Treatments

Treatment for ARFID has advanced substantially since the diagnosis was formalized in 2013, though the evidence base remains smaller than for other eating disorders. Several approaches have demonstrated effectiveness, and understanding what each offers will help you make informed decisions about your own treatment.

CBT-AR (Cognitive Behavioral Therapy for ARFID)

CBT-AR, developed by Jennifer Thomas and Kamryn Eddy at Massachusetts General Hospital, is the most extensively studied treatment specifically designed for ARFID. It is a structured, manual-based protocol delivered over 20 to 30 sessions, organized into four stages.

Exposure-Based Approaches

Exposure is the active ingredient in most ARFID treatment, whether delivered within CBT-AR or as a standalone approach. Effective exposure for ARFID follows six principles.

Start with sensory exploration, not eating. The first step with a new food is not putting it in your mouth. It is looking at it, touching it, smelling it, and tolerating its presence. This graduated approach prevents the exposure from triggering the full threat response that would make the experience counterproductive.

The patient controls the pace. Forced exposure does not work. The person with ARFID decides when to move from one step to the next. Autonomy is essential because the goal is to build new associations with food, and associations formed under coercion tend to be negative.

Consistency matters more than intensity. Small, regular exposures produce better outcomes than occasional heroic attempts. Five minutes of calm food exploration every day builds more neural change than one stressful hour per week.

Track distress, not consumption. The goal of any single exposure session is not to eat the food. It is to reduce the distress associated with the food. If a person handles a food they previously could not touch and their anxiety drops from an 8 to a 4, that is a successful exposure regardless of whether they ate any of it.

Expect non-linear progress. Foods that seemed conquered may become difficult again during stress, illness, or transitions. This is normal and does not mean the treatment is failing.

Avoid pairing exposure with pressure, rewards, or punishment. External incentives contaminate the learning process. The food needs to become intrinsically less threatening, not just worth tolerating for a reward.

FBT Adaptations (Family-Based Treatment)

Family-Based Treatment, originally developed for anorexia nervosa, has been adapted for ARFID in youth. The adapted model retains the core FBT principle that parents take temporary charge of feeding, but modifies the approach to account for ARFID-specific mechanisms.

In FBT for ARFID, parents do not push the child to eat more of feared foods. Instead, they ensure regular meals and snacks, provide consistent exposure opportunities within a low-pressure framework, and gradually shift responsibility back to the child as their eating expands.

FBT adaptations for ARFID are particularly useful for younger children whose eating restriction has resulted in medical compromise, because the structured parental involvement ensures adequate nutrition while treatment progresses.

Medication

No medication is FDA-approved specifically for ARFID, but several are used off-label to address specific ARFID mechanisms.

Cyproheptadine. An antihistamine with appetite-stimulating properties, cyproheptadine is sometimes prescribed for low-interest ARFID, particularly in young children. It can increase hunger signals that are otherwise absent or weak. Evidence is limited to case reports and small studies, but clinical experience suggests benefit for some patients.

SSRIs (Selective Serotonin Reuptake Inhibitors). For fear-based ARFID with significant comorbid anxiety, SSRIs may reduce the baseline anxiety level enough to make exposure-based treatment feasible. They are typically used as an adjunct to therapy rather than a standalone treatment.

Other medications. Mirtazapine (which has appetite-stimulating side effects), low-dose olanzapine, and D-cycloserine (which may enhance exposure learning) have all been explored in small studies or case reports. None has sufficient evidence to recommend as a primary treatment.

Medication is generally most useful when it addresses a specific barrier to treatment engagement. If anxiety is so high that the person cannot participate in exposure work, an SSRI may lower the floor enough to begin. If appetite is so absent that the person is losing weight despite wanting to eat, cyproheptadine may provide the physiological push they need. Medication alone, without behavioral intervention, is unlikely to produce lasting change in ARFID.

Occupational Therapy

Occupational therapists specializing in feeding disorders bring a valuable perspective to ARFID treatment, particularly for sensory-based presentations. OT-based feeding therapy focuses on systematic desensitization to sensory properties of food, oral motor skill development, and building tolerance for the sensory experience of eating.

For children, OT feeding therapy often incorporates play-based approaches that reduce the threat associated with food exploration. Messy play with food-like textures, cooking activities that involve handling ingredients without pressure to eat them, and graded sensory exposure through art and craft activities with food materials can all build the foundation for eventual eating.

OT is particularly valuable for individuals whose ARFID involves oral motor difficulties (sensitivity to certain textures because of how they feel during chewing or swallowing) and for young children who need a developmental approach to feeding skill acquisition.

How to Choose Treatment

If your primary presentation is fear-based, CBT-AR or another structured exposure-based therapy is likely your best starting point. The anxiety treatment components of CBT-AR map directly onto the maintaining mechanism.

If your primary presentation is sensory-based, a combination of CBT-AR and occupational therapy may be most effective. OT can address the sensory foundation while CBT-AR provides the structured exposure protocol.

If your primary presentation is low interest, CBT-AR’s focus on regular eating patterns and interoceptive awareness is relevant, and medication (particularly cyproheptadine) may be a useful adjunct.

If you are a child or adolescent with medical compromise, FBT adaptations provide the parental structure needed to ensure nutritional safety while treatment progresses.

If you are autistic, seek a provider who has experience adapting ARFID treatment for autistic individuals. Standard protocols may need modification to account for sensory processing differences, communication preferences, and the role of predictability.